Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C

Liver International

Volumn 27, Issue 5, 2007, Pages 612-619

  Ciccorossi, Pietro ^a   Maina, Anna Maria ^a   Oliveri, Filippo ^a   Petruccelli, Stefania ^b   Leandro, Gioacchino ^c   Colombatto, Piero ^a   Moriconi, Francesco ^a   Mosca, Franco ^d   Filipponi, Franco ^b   Bonino, Ferruccio ^b   Brunetto, Maurizia Rossana ^a  

^a Azienda Ospedaliero Universitaria Pisana   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UO Gastroenterologia Castellana Grotte ^*  (Italy)

^d UO Chirurgia Generale e Trapianti   (Italy)

Author keywords

Antiviral therapy; Liver biopsy; Recurren thepatitis C; Viral kinetics

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; INTERFERON; METHYLPREDNISOLONE; PLACEBO; RIBAVIRIN; VIRUS RNA;

ACUTE HEPATITIS; ADULT; AGE; ARTICLE; CADAVER DONOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; EARLY DIAGNOSIS; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; NONHUMAN; POSTOPERATIVE CARE; POSTOPERATIVE INFECTION; RECURRENT INFECTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; VIREMIA; VIRUS LOAD;

ADULT; AGE FACTORS; AGED; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEPATITIS C, CHRONIC; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 34547104583     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01459.x     Document Type: Article

References (34)

1. Brown RS. Hepatitis C and liver transplantation. Insight Rev Nat 2005; 436: 973-8.
2. Araya V, Rakela J, Wright T. Hepatitis C after liver transplantation. Gastroenterology 1997; 112: 575-82.
3. Shiffman ML, Vargas HE, Everson GT. Controversies in the management of hepatitis C virus infection after liver transplantation. Liver Transplant 2003; 9: 1129-44.
4. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-96.
5. Berenguer M, Natural history of recurrent hepatitis C. Liver Transplant 2002; 8: S14-8.
6. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. Rev J Hepatol 2001; 35: 666-78.
7. Berenguer M, Ferrel L, Watson J, et al. HCV-related fibrosis progression after liver transplantation: Increase in recent years. J Hepatol 2000; 32: 673-84.
8. Neumann UP, Berg TP, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41 (5): 830-60.
9. Wiesner RH, Sorrel M, Villamil F the International Liver Transplantation Society Expert Panel. Report of the first international Liver Transplantation and hepatitis C. Liver Transplant 2003; 9 (Suppl. 3): S1-9.
10. Doughty AL, Spencer JD, Cossart YE, McCaughan GW. Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels. Liver Transplant Surg 1998; 4: 15-21.
11. Feray C, Gigou M, Samuel D, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995; 108: 1088-96.
12. Prieto M, Berenguer M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999; 29: 250-6.
13. Berenguer M, Prieto M, Còrdoba J, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: Association with treatment of rejection. J Hepatol 1998; 28: 756-63.
14. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-10.
15. Machicao VI, Bonatti H, Krishna M, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004; 77: 84-92.
16. Marina Berenguer. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transplant 2003; 9: S44-7.
17. Chazouilleres O, Kim M, Combs C, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994; 106: 994-9.
18. Gretch DR, Bacchi CE, Corey L, et al. Persistent hepatitis C virus infection after liver transplantation: Clinical and virological features. Hepatology 1995; 22: 1-9.
19. Charlton Michael. Liver biopsy, viral kinetics and the impact of viraemia on severity oh hepatitis C virus recurrence. Liver Transplant 2003; 9: S58-62.
20. Sreekumar R, Koch AG, Kendler YM, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32: 1125-30.
21. Gane EJ, Naoumov NV, Qian KP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167-77.
22. Papatheodoridis GV, Barton SGRG, Andrew D, et al. Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: The role of different immunosuppressive regimens. GUT 1999; 45: 427-34.
23. Filipponi F, Callea F, Salizzoni M, et al. Double-blind comparison of hepatitis C histological recurrence rate in HCV+liver tranplant recipients given basiliximab+steroids or basiliximab+placebo, in addition to cyclosporine and azathioprine. Transplantation 2004; 78: 1488-95.
24. Ishak K, Baptista A, Bianchi L, et al. Histolgical grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
25. International Working Party. Terminology for hepatic allograft rejection. Hepatology 1995; 22: 648-54.
26. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852-8.
27. Retortillo MG, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-7.
28. Powers KA, Ribeiro RM, Patel K, et al. Kinetics of hepatitis C virus reinfection after liver tranplantation. Liver Transplant 2006; 12: 207-16.
29. Mazzaferro V, Tagger A, Schiavo M, et al. Prevention of recurrent Hepatitis C after Liver Transplantation with early interferon and ribavirin treatment. Transplant Proc 2001; 33: 1355-7.
30. Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after liver transplantation: A nonrandomized trial of interferon α alone versus interferon α and ribavirin. Liver Transplant 2001; 7: 863-9.
31. Lavezzo B, Franchello A, Smedile A, et al. Treatment of recurrent hepatitis C in liver tranplants: Efficacy of a six versus a twelve month course of intereferon alfa 2b with ribavirin. J Hepatol 2002; 37: 274-6.
32. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon α2a for hepatitis C after liver transplantation: Two randomized controlled trials. Hepatology 2005; 41: 289-98.
33. Berenguer M, Palau A, Fernandez A, et al. Efficacy, predictors of response and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transplant 2006; 12 (7): 1067-76.
34. Ciccorossi P, Filipponi F, Oliveri F, et al. Increasing serum levels of IgM anti-HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares. J Viral Hepat 2003; 10: 168-73.